Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients

Link copied to
clipboard

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Tryptamine Therapeutics’ (ASX:TYP) recent trial showing pain reduction in every patient.

The trial was undertaken with the University of Michigan and dosed the patients with Tryptamine’s oral psilocybin formulation.

Tune in to get the latest.

While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

This field is hidden when viewing the form

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

Spotlight

Comments

This field is for validation purposes and should be left unchanged.

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

Health & Biotech

Tryptamine completes psilocin-based IV-infusion study in obese subjects

November 29, 2024 | Special Report

Health & Biotech

Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study

November 22, 2024 | Special Report

Break It Down

Break it Down: Cash in the bag for Tryptamine Therapeutics

October 30, 2024 | Stockhead TV